Article info

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

Authors

  • Casey R Ager Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USADepartment of Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USAColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Urology, Mayo Clinic Arizona, Scottsdale, Arizona, USA PubMed articlesGoogle scholar articles
  • Mingxuan Zhang Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USADepartment of Molecular Pathology and Therapeutics, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Matthew Chaimowitz Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Shruti Bansal Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Somnath Tagore Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USADepartment of Systems Biology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Aleksandar Obradovic Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USADepartment of Systems Biology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Collin Jugler Department of Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA PubMed articlesGoogle scholar articles
  • Meri Rogava Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USAColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Johannes C Melms Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USAColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Patrick McCann Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Catherine Spina Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Charles G Drake Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USAColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Urology, Mayo Clinic Arizona, Scottsdale, Arizona, USAJanssen Research and Development, Janssen Pharmaceuticals, Spring House, Pennsylvania, USAHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Matthew C Dallos Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USAHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USADepartment of Urology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Benjamin Izar Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USAColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USADepartment of Systems Biology, Columbia University Irving Medical Center, New York, New York, USAHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USAColumbia University Vagelos College of Physicians and Surgeons, New York, New York, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Casey R Ager; ager.casey{at}mayo.edu; Dr Benjamin Izar; bi2175{at}cumc.columbia.edu
View Full Text

Citation

Ager CR, Zhang M, Chaimowitz M, et al
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

Publication history

  • Accepted August 8, 2023
  • First published September 1, 2023.
Online issue publication 
December 06, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.